Shrooms and Antidepressants: What Actually Happens

This question gets answered backwards almost everywhere online. The fear is serotonin syndrome. What actually happens on an SSRI or SNRI is that the mushrooms do less, and serotonin toxicity from that pairing is uncommon, because psilocybin does not work the way MDMA works. The medication that should genuinely stop you is lithium.

Where you stand, by medication

• SSRI or SNRI: expect a weaker trip, more so the longer you have been on it. Serotonin toxicity risk from this pair alone is low. The common failure mode is taking more to compensate.
• Lithium: no. Seizures. This is the hard stop.
• MAOI: the interaction runs the other way. More drug, less predictably, and this is the one class where serotonin toxicity is a live concern.
• Tricyclic: probably amplified, on thin evidence. A reason for caution and a smaller dose.
• Bupropion or mirtazapine: less blunting in survey data, and no controlled interaction data with psilocybin worth leaning on.

Why psilocybin is not MDMA

Psilocybin is a prodrug. Your body converts it to psilocin, which acts directly on serotonin 5-HT2A receptors: it binds the receptor and switches it on. MDMA instead reverses the serotonin transporter and floods the synapse, hitting every serotonin receptor at once. That flooding is what makes MDMA plus an MAOI potentially lethal, and it is why the MDMA and SSRI interaction works out as it does: the SSRI occupies the transporter MDMA needs, so it partly cancels the drug.

Psilocin has no use for the transporter, so an SSRI cannot block its route to the receptor. What an SSRI can do is change the receptor population. Weeks of elevated synaptic serotonin desensitise and downregulate 5-HT2A, and that is the leading explanation for blunted psychedelics on long-term treatment. It is inferred from receptor pharmacology rather than measured in people taking mushrooms, so hold it as a plausible mechanism, not a proven one.

The trials and the surveys disagree

Becker and colleagues in Basel ran the controlled version: a randomised, double-blind, placebo-controlled crossover in healthy volunteers, pretreating with escitalopram at 10 mg/day for 7 days and then 20 mg/day for 7 days before a 25 mg dose of psilocybin. Escitalopram had no relevant effect on the positive mood effects, but it significantly reduced bad drug effects, anxiety, and adverse cardiovascular effects. A 2023 open-label study gave 25 mg psilocybin to 19 people with treatment-resistant depression who stayed on their SSRI throughout, and reported no serious treatment-emergent adverse events and no signal of increased suicidal ideation.

Two weeks of escitalopram is not two years of it, and 19 people is not a safety database. Within those limits, the controlled work shows neither danger nor an erased trip.

The survey data is bigger, covers far longer exposure, and sits a tier lower. The Johns Hopkins retrospective study collected 611 reports of mushroom use during SSRI or SNRI treatment: weaker-than-expected effects in roughly 47% of SSRI users and 55% of SNRI users, against 29% for bupropion, which is not serotonergic. Retrospective self-report has the usual problems, including unverified doses and substances, recall bias, and the fact that nobody writes in about an unremarkable evening. The bupropion comparison is what makes the pattern hard to wave away.

So: people on months or years of treatment frequently report blunting, while two weeks of controlled pretreatment mainly sands off the rough edges. Treatment duration is the most likely reason those findings differ. Sarparast’s 2022 systematic review of psychedelic drug interactions turned up 24 MDMA studies and only five involving psilocybin, which is a fair summary of how much there is to reason from.

If you are on one of these and the mushrooms do nothing, the tempting move is to double the next dose. That is how people end up somewhere much heavier than they planned, because blunting is not consistent between sessions and it is not consistent between people.

Serotonin toxicity, and why it is not the main risk here

Serotonin toxicity needs excess serotonin sitting in the synapse, and it is overwhelmingly a problem of combinations that raise intrasynaptic serotonin alongside an MAOI. Malcolm and Thomas reviewed the pharmacology in 2021 and concluded that psychedelics without an MAOI present low risk of serotonin toxicity alongside non-MAOI serotonergic drugs. Psilocin is a direct receptor agonist, not a releaser and not a reuptake inhibitor, so it does not add serotonin to the synapse. That is the mechanistic reason the feared scenario is not the likely one.

Low risk is not no risk, and the signs are worth knowing anyway. The Hunter criteria look for:

• Spontaneous or inducible clonus, meaning rhythmic involuntary muscle contraction
• Agitation with sweating
• Hyperreflexia with tremor
• Temperature above 38°C with muscle rigidity

If that picture appears, stop everything, cool the person, and get to an emergency room. The hyperthermia comes from muscle activity rather than a fever response, so paracetamol and ibuprofen will not touch it.

Lithium is the one to take seriously

Nayak and colleagues went through online experience reports and found that 47% of 62 lithium plus classic psychedelic reports described a seizure, with another 18% describing other medical or psychological emergencies. Zero of 34 lamotrigine reports involved a seizure. Those reports included psilocybin, not only LSD, which is what you would expect from a class that shares the 5-HT2A mechanism.

A population-based survey of 613 lifetime psychedelic users found that among people reporting a psychedelic-related seizure, nearly half were taking antidepressants, mood stabilisers, or opioid replacement therapy at the time. And a 2024 case report documented new-onset seizures in an adolescent who took LSD on a low dose of lithium, so keeping your level down is not a workaround.

All of that is case-report tier, with unverified doses and substances. It is still the strongest signal in this entire topic and the direction of it is not ambiguous. Our full write-up is at LSD and lithium, and all of it applies to mushrooms.

MAOIs and tricyclics

Monoamine oxidase A metabolises psilocin, so inhibiting it raises exposure and stretches it out. Phenelzine, tranylcypromine, moclobemide, selegiline, and the antibiotic linezolid all count, as do the harmala alkaloids in ayahuasca-style preparations. You get more drug rather than less, arriving less predictably.

The tricyclic picture rests on one retrospective questionnaire from 1996 covering ten people who used LSD during antidepressant treatment. Chronic tricyclic use was associated with increased physical, hallucinatory, and psychological responses, as was chronic lithium, while MAOIs were associated with decreased LSD effects. Ten people, retrospective, LSD rather than psilocybin, and the MAOI result runs against the pharmacology. Take the tricyclic signal as a weak reason for caution, not a known quantity.

Do not quit your meds to trip

Coming off an SSRI or SNRI abruptly produces brain zaps, dizziness, flu-like symptoms, and mood destabilisation. Stopping lithium abruptly is associated with rebound mania and fast relapse. Those are the reasons people expect.

The one people do not expect is that it probably will not even work. In the Hopkins survey, about 30% of people still reported reduced effects three to six months after stopping an SSRI or SNRI. Receptor adaptation does not clear on the same schedule as the molecule.

If a taper is genuinely on the table for you, that belongs in a conversation with whoever prescribes it, planned around your mental health rather than around a festival date.

Check your specific combination with our drug interaction checker, and read the psilocybin harm reduction guide for dosing and risk basics. If a session is coming up, the safe psilocybin trip guide covers set, setting, and what to do when things go sideways, shrooms and supplements covers what to take and skip around it, and can you overdose on mushrooms covers what an overwhelming dose actually looks like.

Sources

PMID 37291890 | PMID 34251464 | PMID 34348413 | PMID 34743319 | PMID 37443386 | PMID 35253070 | PMID 35981469 | PMID 38986146 | PMID 8788508